Contract Pharma5 小时
FDA Grants Priority Review for Sobi’s Gamifant in HLH/MAS
The U.S. Food and Drug Administration (FDA) has accepted Sobi’s supplemental Biologics License Application (sBLA) for ...
The Pharma Letter4 小时
FDA priority review for Sobi’s Gamifant sBLA
The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Gamifant (emapalumab-Izsg), submitted by Swedish Orphan Biovitrum, the Nordic biotech also ...
Nature1 个月
Adult-Onset Still's Disease and Macrophage Activation Syndrome
A significant complication associated with AOSD is Macrophage Activation Syndrome (MAS), a severe inflammatory condition that can occur in patients with AOSD, leading to life-threatening ...
US FDA grants Priority Review to Sobi's supplemental Biologics Licence Application (sBLA ...
Sobi® (STO: SOBI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Gamifant® (emapalumab-Izsg) for use in adult ...
Swedish Orphan Biovitrum AB: US FDA grants Priority Review to Sobi's supplemental Biologics ...
Sobi® (STO: SOBI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) ...
eLife9 天
Synovial macrophage diversity and activation of M-CSF signaling in post-traumatic ...
Joint injury induces rapid and sustained diversification of resident and infiltrating synovial macrophage phenotypes, underpinning osteoarthritis-associated synovitis.
Cure Today14 天
Breyanzi Improves Responses in R/R Indolent B-Cell Non-Hodgkin Lymphoma
Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...